Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > MWMan

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon May 04, 2023 2:39am

129 Views

Post# 35429252

RE:RE:RE:RE:RE: MWMan

That's not true...

We have no idea of how much the deal with Abbvie is worth including milestones and royalty.

The only piece of information is the upfront that fell short on our expectations, but the total value? No idea.

Management know that anti-aging is the crown juvel and is heavily invested - if the future exit will be successful it depends on the upcoming deal. It's now or never.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”